{"name":"Navidea Biopharmaceuticals","slug":"navidea-biopharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":65652,"revenueGrowth":-87.6,"grossMargin":0,"rdSpend":5969774,"netIncome":-15177153,"cash":4371606,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tc 99m tilmanocept","genericName":"Tc 99m tilmanocept","slug":"tc-99m-tilmanocept","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Tc 99m tilmanocept","genericName":"Tc 99m tilmanocept","slug":"tc-99m-tilmanocept","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWk1jeS0wMFZnb0xQdzRfWndNV3pNVm1ZdVRNRjc1alB1ZmZlUDUweWhNUVMycEo1MVhUQ2JwbW1Fc3BpTUx3bzdKb0JybFVMVjAzYmg1a0tBX3hCMDBsUVU0WmNaWFNZZjByMTg1Rzh5QVBtRnd2S2JmenV3RDN4MEhEQTVmZEpiV1pLR2JkSGU4RjBObFdNaWhudi1CU3AzeDBhUTZMMzhocU01WldVNHRnR2NPMkRYWTNJ?oc=5","date":"2026-02-26","type":"pipeline","source":"AD HOC NEWS","summary":"Navidea's Restructuring Journey: Equity Value Hangs in the Balance - AD HOC NEWS","headline":"Navidea's Restructuring Journey: Equity Value Hangs in the Balance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNRzJLeXZVSm1lZk1ZclloelhBMzRpSUpCeXpYM3hXTXpIYWprQmtUaUU0QTRTVkZkWkZDMTNTMzctV3Y2cmg0emNaUzVsZlJmNTRsVDBRalNrRzE1eXVxWHRLRjBzeFdOa2kyWGtVYUpCd0g0bWRkRW1HQVByUXRmVGxERlZkNHVSYkZXMzEyRzZnaEJoR1VGaEdLYk4zaTQ4enAxTXNXZw?oc=5","date":"2025-10-09","type":"pipeline","source":"Contract Pharma","summary":"Navidea Biopharmaceuticals Files for Chapter 11 Bankruptcy - Contract Pharma","headline":"Navidea Biopharmaceuticals Files for Chapter 11 Bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5TTXp5OTloUUdDQmV4Sm4wQUJVb3RrMHJ3aW0wdGRtdmxPa2NQWTJVREJsVm9DZnFTUHVKXzNsZkFuYnFscVE3bnlEbW9rcW42NUh3?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"SYRS Stock Price, News & Analysis - Stock Titan","headline":"SYRS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQbGdvVFdOQkQyQ016WmtQQ2ZTRU81cWE1VnFFNnFMd2t5bU41Nzh6UURXcVk1YkRHWGkxYlFsMzU1U3VKYnBobGgxSUNBRXZ2VmZiaXhqUnRsclhZbTBIVURxSlF0UmZDM3I4R2E2M0pqcUdSRTdDdDlJdi16QjBCZWU2SzJlalVnXzd1M2kyVFVBaDZ0Rmp1ZlBDeEUtY0FSOHUzN1hiSjAtSWdXN1NWQnZDTE9nbXJGb1VSUkdEQmJFV1ZTcTRkb3lVMVFkcWJyM1ljQTBYSWh1M3BwaTBoMFFVYWJuRHNTYlNjNA?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire UK","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNbmQ2d0xiRFEtbjdsQldaOU1aV2xsZUk5RHZCR0dBeFNWUlY4eFUxdlVmdnFSZXB4WXJ4cFI3ZXd1d3dZM3dqWl9TYUthNDZtMVBpZVo5MU1sZGZSMmMtSHRZRmJ1NmJYVy12aVNHbnl0bkZxX09RcXJRUlFVbml3OUJLZXEyT2o2blVRdmJR0gGTAUFVX3lxTFAteE8yNGlhYWRIUTljTXdpblZ1Y0QxU3JpbUVRdDJna3JLOThDRU9BN0xLMklkb3oxV0RPVWRNOUVVYVJxVlBFdmFoTnB2UVZudXlVa2RTalRzZ0M1TTZHRWJWbWdlcG85U1NVWWFyaGpvcjlkLXlkOXNvdXBqa3hRZmJza3UwTTdRNm91MlBEWXhRYw?oc=5","date":"2017-06-29","type":"pipeline","source":"Express Pharma","summary":"NPPA revised ceiling price of 761 drugs under GST rates - Express Pharma","headline":"NPPA revised ceiling price of 761 drugs under GST rates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQTEpNLUQ0MUN4UElqMkV6UWxBd01ubjd6a19CV0U2c1gzbDRYb3lIQjVOUVBwTl84UTRBSkR0aFNGMU1SUUkxVFRESEh1elctU3VkSU04emhwdFRWWGJONVV3cjM4cjZzUEZ1Z2VaRF9GV3g1ZUJ4b2JNemEyTWRlSzdmZ1h5dHpoRXk0OA?oc=5","date":"2016-07-27","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Pfizer Places High Bid of $40M for BIND Therapeutics - Genetic Engineering and Biotechnology News","headline":"Pfizer Places High Bid of $40M for BIND Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQaU1NNTFYb0h0b1N0czNzczM0Z1hkZXZnazFsNEpqVlRmRUt5eFJFZXdZdkQ4MHB3RFgwTjA1NHBYV0w1MWxkWjRROUtaaTloY0ZXM1RKTnVYaUIwRUt0b3JZVU9KX3NaQUVMY1k3MEJaT2RKdGM5UlN3dllTX2tpcVZiaGUxOU9iS2h3R053blM4ZUxDdzVGazhYbmt5RDgybEtFSng3TU80UEY4b0FRLVh3Q1h4dw?oc=5","date":"2016-05-30","type":"pipeline","source":"Fierce Pharma","summary":"Navidea scores $1.8M in NIH grant for Kaposi's sarcoma research - Fierce Pharma","headline":"Navidea scores $1.8M in NIH grant for Kaposi's sarcoma research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQVEZKdU1rZDJ2X1FMcGxQcjMweG8ydkRydENodU9MMGxFV25Fd09BakpUT0dmVXF1dUw0cFFQQnAwdHFKZlpkTTRTV1ZrOEJBZ2ktdG5kaEhvZHFfRDBCSDBDX05GckVpSy1sVVYxY1RfcXhmaWJXdFdsdXNPbVh2MXlmQkFYcXUwRWVSWlVOdDN0WDlmNDI0aA?oc=5","date":"2015-09-26","type":"pipeline","source":"statnews.com","summary":"Biotech exec Martin Shkreli has history of tough tactics - statnews.com","headline":"Biotech exec Martin Shkreli has history of tough tactics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBVZFZKbjV6V0xpWHgxdFNJWXlEbjdDUmZVSmY0OWN0MldNdV9LYS1RbTc1cGNIckdHT3NlSEhiWVNxSWxCRGc2RU0xX0tyb2xTNm52ZmN3WQ?oc=5","date":"2015-06-18","type":"pipeline","source":"MarketBeat","summary":"Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis - MarketBeat","headline":"Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":65652,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":65652,"period":"2022-12-31"},{"value":531513,"period":"2021-12-31"},{"value":531513,"period":"2021-12-31"},{"value":915013,"period":"2020-12-31"},{"value":915013,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5969774,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-15177153,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4371606,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}